NDA 218698 · Xtm Consulting
Lopressor
Metoprolol Tartrate · Oral
Last checked: Nov 19, 2026Latest source record: Jun 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 28, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
302
56 Phase 3, 19 recruiting
FAERS reports
86,471
59,888 serious, 9,924 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 29, 2026.
1. INDICATIONS AND USAGE Metoprolol Tartrate Tablets is a beta-adrenergic blocker indicated in the treatment of hemodynamically stable adult patients with myocardial infarction, to reduce the risk of cardiovascular mortality. ( 1.1 ) 1.1 Myocardial Infarction Metoprolol Tartrate Tablets is indicated in the treatment of hemodynamically stable adult patients with myocardial infarction (MI) to reduce cardiovascular mortality.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LOPRESSOR · METOPROLOL TARTRATE 12.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial InfarctionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00222573 · 46,000 participants · Start Jul 1999
Drug: clopidogrel and metoprolol · For: Acute Myocardial Infarction
Sites: Beijing, China; Oxford, United Kingdom
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- POISE Trial: Perioperative Ischemic Evaluation StudyPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT00182039 · 8,351 participants · Start Oct 2002 · Primary completion Jul 2007
Drug: Metoprolol controlled release (CR); Placebo · For: Cardiovascular Diseases
Sites: Hamilton, Canada
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)Pivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT03278509 · 5,000 participants (planned) · Start Sep 11, 2017 · Primary completion Nov 16, 2023
Drug: Metoprolol Succinate; Bisoprolol · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Danderyd, Sweden
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT03646357 · 2,895 participants · Start Oct 1, 2018 · Primary completion Apr 4, 2025
Drug: Betablocker · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Arendal, Norway; Bergen, Norway; Bodø, Norway · 20 sites in all
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection FractionPivotal-lookingActive, not recruiting
Bispebjerg HospitalAcademic, hospital or other
NCT03778554 · 2,760 participants (planned) · Start Dec 17, 2018 · Primary completion Apr 1, 2025
Drug: Metoprolol Succinate; Bisoprolol and 2 more · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue5,878
- nausea5,108
- dyspnoea5,035
- diarrhoea5,014
- dizziness3,953
- death3,874
- drug ineffective3,796
- pain3,713
- asthenia3,684
- headache3,255
- fall3,119
- myocardial infarction3,041
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,399 |
| 2005 | 1,811 |
| 2006 | 2,035 |
| 2007 | 1,422 |
| 2008 | 3,265 |
| 2009 | 2,706 |
| 2010 | 3,627 |
| 2011 | 5,835 |
| 2012 | 5,503 |
| 2013 | 2,009 |
| 2014 | 3,994 |
| 2015 | 4,233 |
| 2016 | 5,398 |
| 2017 | 5,594 |
| 2018 | 5,556 |
| 2019 | 5,428 |
| 2020 | 4,735 |
| 2021 | 3,713 |
| 2022 | 3,691 |
| 2023 | 3,488 |
| 2024 | 3,430 |
| 2025 | 4,141 |
| 2026 | 3,456 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lopressor (Metoprolol Tartrate)
2024 spending
$310K
Beneficiaries
257
901 claims
Per beneficiary
$1,204
$2.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $518,195 |
| 2021 | $487,155 |
| 2022 | $459,116 |
| 2023 | $369,969 |
| 2024 | $309,517 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, et al. · J Am Coll Cardiol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. · Lancet 2003 · Clinical Trial, Comparative Study
- Metoprolol (Lopressor).
· Med Lett Drugs Ther 1978 · Clinical Trial, Comparative Study
- Metoprolol in Critically Ill Patients With COVID-19.
Clemente-Moragón A, Martínez-Milla J, Oliver E, et al. · J Am Coll Cardiol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Hegde SM, Wang X, Garcia-Pavia P, et al. · J Am Coll Cardiol 2025 · Randomized Controlled Trial, Comparative Study
- Effect of metoprolol on chest pain in acute myocardial infarction.
Herlitz J, Hjalmarson A, Holmberg S, et al. · Br Heart J 1984 · Clinical Trial, Randomized Controlled Trial
Sponsor: Xtm Consulting
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.